Findings highlight the advantages of Adolores approach for the delivery of proprietary gene therapy directly to specialized painsensing peripheral nerves nociceptors that mediate profound analgesia with the potential to address the great unmet need for nonopioid chronic pain therapiesData further supports the clinicaltranslational value of Adolores proprietary nonopioid analgesics for treating... Lire le communiqué |
|
|
|
|
Patent and CA8 gene therapy technology licensed by Adolore BioTherapeutics from the University of MiamiCompany advancing development of rdHSVCA8 gene therapy for the treatment of chronic osteoarthritis OA knee pain toward an INDDELRAY BEACH, FL / ACCESSWIRE / March 4, 2024 / Adolore BioTherapeutics "Adolore" or the "Company", a biotechnology company focused on developing... Lire le communiqué |
|
|
|
|
DELRAY BEACH, FL / ACCESSWIRE / January 30, 2024 / Adolore BioTherapeutics "Adolore" or the "Company", a biotechnology company focused on developing breakthrough opioidfree gene therapy treatments for chronic pain, today announced that Roy C. Levitt, MD, the Companys founder and Executive Chairman, Clinical Professor, University of Miami, and Principal Investigator of a NIH,... Lire le communiqué |
|
|
|
|
Innovative rdHSVbased CA8 gene therapy demonstrates preclinical proofofconcept as a diseasemodifying longacting local analgesic to replace opioids in chronic osteoarthritis OA knee pain managementDELRAY BEACH, FL / ACCESSWIRE / December 5, 2023 / Adolore BioTherapeutics "Adolore" or the "Company", a biotechnology company focused on developing breakthrough opioidfree gene... Lire le communiqué |
|
|
|
|
Live moderated webcast with Roelof Rongen, Chief Executive Officer of Adolore BioTherapeutics on Wednesday, October 25th at 3:00 PM ETDELRAY BEACH, FL / ACCESSWIRE / October 11, 2023 / Adolore BioTherapeutics "Adolore" or the "Company", a company focused on developing breakthrough opioidfree gene therapy treatments for chronic pain, today announced that Roelof Rongen,... Lire le communiqué |
|
|
|
|
UH3 Award follows the successful completion of an initial NIH/NINDS HEAL UG3 grant for which all preclinical milestones were metThis NIH/NINDS HEAL UH3 Award will support all formal preclinical GLP/GMP/GCP development work through a firstinhuman study in patients, undertaken in collaboration with Adolore BioTherapeutics and expected to commence in 2026DELRAY BEACH, FL / ACCESSWIRE / October 3,... Lire le communiqué |
|
|
|
|